
CAS 1434635-54-7
:Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
7 produits concernés.
ND-630
CAS :Formule :C28H31N3O8SDegré de pureté :97%Couleur et forme :SolidMasse moléculaire :569.6260Ref: IN-DA01EN4Y
1gÀ demander5gÀ demander10gÀ demander25gÀ demander2mg63,00€5mg71,00€10mg103,00€25mg153,00€50mg175,00€100mg487,00€250mg585,00€(R)-2-(1-(2-(2-Methoxyphenyl)-2-((Tetrahydro-2H-Pyran-4-Yl)Oxy)Ethyl)-5-Methyl-6-(Oxazol-2-Yl)-2,4-Dioxo-1,4-Dihydrothieno[2,3-d]Pyrimidin-3(2H)-Yl)-2-Methylpropanoic Acid
CAS :(R)-2-(1-(2-(2-Methoxyphenyl)-2-((Tetrahydro-2H-Pyran-4-Yl)Oxy)Ethyl)-5-Methyl-6-(Oxazol-2-Yl)-2,4-Dioxo-1,4-Dihydrothieno[2,3-d]Pyrimidin-3(2H)-Yl)-2-Methylpropanoic AcidDegré de pureté :97%Masse moléculaire :569.63g/molFirsocostat
CAS :<p>Firsocostat (GS-0976) is an inhibitor of acetyl-CoA carboxylase (ACC) dimerization that inhibits human ACC1 and ACC2 activity (IC50s of 2.1 and 6.1 nM).</p>Formule :C28H31N3O8SDegré de pureté :98% - 98.46%Couleur et forme :SolidMasse moléculaire :569.63ND-630
CAS :<p>ND-630 is a drug that has been designed to treat metabolic disorders by targeting the transcription-polymerase chain reaction of the epidermal growth factor. It has been shown to alleviate liver lesions and hepatic steatosis in mice. ND-630 may also be a potential biomarker for hepatocyte injury, as it has been shown to have an effect on energy metabolism and lipid synthesis. There is also some evidence that ND-630 may be used as an anthelmintic drug.</p>Formule :C28H31N3O8SDegré de pureté :Min. 95%Masse moléculaire :569.63 g/mol




